$ICCRW
iCoreConnect Inc. Stock $iccrw

$iccrw Overview Financials Valuation SEC Filings Company Website

2021 Q3 Form 10-Q Financial Statement

#000147793221005897 Filed on August 23, 2021

Income Statement

Concept	2021 Q3	2021 Q2	2020 Q2
Revenue	$1.365M	$981.4K	$472.0K
YoY Change	157.57%	107.92%	54.75%
Cost Of Revenue	$420.9K	$267.7K	$210.0K
YoY Change	53.62%	27.49%	176.32%
Gross Profit	$944.2K	$713.7K	$262.0K
YoY Change	268.83%	172.39%	14.41%
Gross Profit Margin	69.17%	72.72%	55.51%
Selling, General & Admin	$1.343M	$1.004M	$870.0K
YoY Change	79.96%	15.39%	12.99%
% of Gross Profit	142.19%	140.67%	332.06%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$383.3K	$218.4K	$225.0K
YoY Change	67.36%	-2.92%	33.93%
% of Gross Profit	40.59%	30.61%	85.88%
Operating Expenses	$1.693M	$1.255M	$1.095M
YoY Change	73.69%	14.57%	16.74%
Operating Profit	-$749.3K	-$540.9K	-$833.0K
YoY Change	4.21%	-35.06%	17.49%
Interest Expense	$97.55K	$92.53K	$34.00K
YoY Change	23.48%	172.14%	-172.34%
% of Operating Profit
Other Income/Expense, Net	-$356.5K	-$1.042M	-$24.00K
YoY Change	548.13%	4242.91%
Pretax Income	-$1.106M	-$1.583M	-$857.0K
YoY Change	42.86%	84.74%	13.36%
Income Tax
% Of Pretax Income
Net Earnings	-$1.106M	-$1.583M	-$857.0K
YoY Change	42.86%	84.74%	13.36%
Net Earnings / Revenue	-81.0%	-161.33%	-181.57%
Basic Earnings Per Share
Diluted Earnings Per Share	-$7.118K	-$10.44K	-$11.82K
COMMON SHARES
Basic Shares Outstanding	151.6M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2021 Q3	2021 Q2	2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$699.2K	$846.0K	$12.00K
YoY Change	819.97%	6950.33%
Cash & Equivalents	$699.2K	$846.0K	$12.00K
Short-Term Investments
Other Short-Term Assets	$181.9K	$132.0K	$12.00K
YoY Change	506.4%	1000.17%	-45.45%
Inventory
Prepaid Expenses
Receivables	$484.1K	$233.9K	$174.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$1.365M	$1.212M	$198.0K
YoY Change	501.39%	512.11%	-7.04%
LONG-TERM ASSETS
Property, Plant & Equipment	$50.60K	$15.09K	$32.00K
YoY Change	-54.0%	-52.84%	-64.44%
Goodwill	$3.074M	$1.291M
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$6.040M	$4.496M	$2.389M
YoY Change	155.61%	88.21%	11.53%
TOTAL ASSETS
Total Short-Term Assets	$1.365M	$1.212M	$198.0K
Total Long-Term Assets	$6.040M	$4.496M	$2.389M
Total Assets	$7.405M	$5.708M	$2.587M
YoY Change	185.92%	120.65%	9.85%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.244M	$833.4K	$1.012M
YoY Change	24.65%	-17.65%	30.92%
Accrued Expenses	$58.50K	$47.04K	$28.00K
YoY Change	53.95%	68.0%	-54.84%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Long-Term Debt Due	$1.198M	$2.372M	$1.058M
YoY Change	-6.81%	124.22%	-17.02%
Total Short-Term Liabilities	$2.511M	$3.284M	$2.103M
YoY Change	7.87%	56.17%	-19.36%
LONG-TERM LIABILITIES
Long-Term Debt	$2.750M	$0.00	$183.0K
YoY Change	2031.53%	-100.0%	245.28%
Other Long-Term Liabilities	$52.66K	$74.44K	$96.00K
YoY Change	-65.36%	-22.46%	-34.25%
Total Long-Term Liabilities	$2.802M	$74.44K	$279.0K
YoY Change	897.27%	-73.32%	40.2%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.511M	$3.284M	$2.103M
Total Long-Term Liabilities	$2.802M	$74.44K	$279.0K
Total Liabilities	$5.314M	$3.359M	$2.382M
YoY Change	103.66%	41.01%	-15.14%
SHAREHOLDERS EQUITY
Retained Earnings	-$81.33M	-$78.95M
YoY Change
Common Stock	$159.2K	$151.6K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$2.092M	$2.350M	$205.0K
YoY Change
Total Liabilities & Shareholders Equity	$7.405M	$5.708M	$2.587M
YoY Change	185.92%	120.65%	9.85%

Cashflow Statement

Concept	2021 Q3	2021 Q2	2020 Q2
OPERATING ACTIVITIES
Net Income	-$1.106M	-$1.583M	-$857.0K
YoY Change	42.86%	84.74%	13.36%
Depreciation, Depletion And Amortization	$383.3K	$218.4K	$225.0K
YoY Change	67.36%	-2.92%	33.93%
Cash From Operating Activities	-$891.6K	-$321.2K	-$252.0K
YoY Change	96.39%	27.45%	-34.2%
INVESTING ACTIVITIES
Capital Expenditures	-$1.434M	-$1.910M	-$130.0K
YoY Change	1056.67%	1369.3%	-20.73%
Acquisitions
YoY Change
Other Investing Activities			$0.00
YoY Change
Cash From Investing Activities	-$1.434M	-$1.910M	-$130.0K
YoY Change	1056.67%	1369.3%	-20.73%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.179M	2.883M	333.0K
YoY Change	239.41%	765.8%	-18.38%
NET CHANGE
Cash From Operating Activities	-891.6K	-321.2K	-252.0K
Cash From Investing Activities	-1.434M	-1.910M	-130.0K
Cash From Financing Activities	2.179M	2.883M	333.0K
Net Change In Cash	-146.9K	651.9K	-49.00K
YoY Change	-329.47%	-1430.33%	-64.75%
FREE CASH FLOW
Cash From Operating Activities	-$891.6K	-$321.2K	-$252.0K
Capital Expenditures	-$1.434M	-$1.910M	-$130.0K
Free Cash Flow	$542.7K	$1.589M	-$122.0K
YoY Change	-264.44%	-1402.39%	-44.29%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	151613399	shares
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	846039	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7619	USD
CY2021Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	233915	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	126472	USD
CY2021Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	132019	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	20103	USD
CY2021Q2	us-gaap	Assets Current AssetsCurrent	1211973	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	154194	USD
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	15090	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2405	USD
CY2021Q2	us-gaap	Goodwill Goodwill	1291109	USD
CY2021Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	118182	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	150477	USD
CY2021Q2	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	698349	USD
CY2020Q4	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	768907	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	517929	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	753794	USD
CY2021Q2	us-gaap	Finite Lived Customer Lists Gross FiniteLivedCustomerListsGross	1855664	USD
CY2020Q4	us-gaap	Finite Lived Customer Lists Gross FiniteLivedCustomerListsGross	369524	USD
CY2020Q4	us-gaap	Goodwill Goodwill	491376	USD
CY2021Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	4496323	USD
CY2020Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	2536483	USD
CY2021Q2	us-gaap	Assets Assets	5708296	USD
CY2020Q4	us-gaap	Assets Assets	2690677	USD
CY2021Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	833416	USD
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1664125	USD
CY2021Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	47035	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	89088	USD
CY2021Q2	us-gaap	Notes Payable Current NotesPayableCurrent	2372271	USD
CY2020Q4	us-gaap	Notes Payable Current NotesPayableCurrent	1429207	USD
CY2021Q2	us-gaap	Deferred Revenue Leases Current DeferredRevenueLeasesCurrent	31586	USD
CY2020Q4	us-gaap	Deferred Revenue Leases Current DeferredRevenueLeasesCurrent	2775	USD
CY2021Q2	us-gaap	Liabilities Current LiabilitiesCurrent	3284308	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3185195	USD
CY2021Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	53699	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	61389	USD
CY2021Q2	us-gaap	Deferred Revenue And Credits Noncurrent DeferredRevenueAndCreditsNoncurrent	20743	USD
CY2020Q4	us-gaap	Deferred Revenue And Credits Noncurrent DeferredRevenueAndCreditsNoncurrent	73033	USD
CY2021Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	74442	USD
CY2020Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	134422	USD
CY2021Q2	us-gaap	Liabilities Liabilities	3358750	USD
CY2020Q4	us-gaap	Liabilities Liabilities	3319617	USD
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	600000000	shares
CY2021Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	151613399	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	90081336	shares
CY2021Q2	us-gaap	Common Stock Value CommonStockValue	151613	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	90081	USD
CY2021Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	81143985	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	77112060	USD
CY2021Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-78946052	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-77831081	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	2349546	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-628940	USD
CY2021Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5708296	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2690677	USD
CY2021Q2	us-gaap	Revenues Revenues	981378	USD
CY2020Q2	us-gaap	Revenues Revenues	472000	USD
	us-gaap	Revenues Revenues	1685379	USD
	us-gaap	Revenues Revenues	978000	USD
CY2021Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	267728	USD
CY2020Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	210000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	507761	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	429000	USD
CY2021Q2	us-gaap	Gross Profit GrossProfit	713650	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-812914	USD
	us-gaap	Gross Profit GrossProfit	1177618	USD
	us-gaap	Gross Profit GrossProfit	549000	USD
CY2021Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1003870	USD
CY2020Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	870000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1860258	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1679000	USD
CY2021Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	250715	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	576178	USD
CY2021Q2	icct	Stock Issued For Cash Amount StockIssuedForCashAmount	1503500	USD
CY2021Q2	icct	Stock Compensation Expense Amount StockCompensationExpenseAmount	68945	USD
CY2021Q2	icct	Stock Issued For Convertible Debt Amount StockIssuedForConvertibleDebtAmount	2730	USD
CY2020Q2	us-gaap	Gross Profit GrossProfit	262000	USD
CY2020Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	225000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	503412	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	448000	USD
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	1254585	USD
CY2020Q2	us-gaap	Operating Expenses OperatingExpenses	1095000	USD
	us-gaap	Operating Expenses OperatingExpenses	2363670	USD
	us-gaap	Operating Expenses OperatingExpenses	2127000	USD
CY2021Q2	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-540935	USD
CY2020Q2	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-833000	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-1186052	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-1578000	USD
CY2021Q2	us-gaap	Interest Expense InterestExpense	92526	USD
CY2020Q2	us-gaap	Interest Expense InterestExpense	34000	USD
	us-gaap	Interest Expense InterestExpense	260323	USD
	us-gaap	Interest Expense InterestExpense	69000	USD
CY2021Q2	us-gaap	Other Income OtherIncome	0	USD
CY2020Q2	us-gaap	Other Income OtherIncome	10000	USD
	us-gaap	Other Income OtherIncome	0	USD
	us-gaap	Other Income OtherIncome	10000	USD
CY2021Q2	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	331404	USD
CY2020Q2	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	0	USD
	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	331404	USD
	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	0	USD
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	238878	USD
CY2020Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-24000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	71081	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-59000	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-302057	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-857000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-1114971	USD
	us-gaap	Net Income Loss NetIncomeLoss	-1637000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	465000	USD
CY2020Q1	icct	Stock Issued For Cash And Conversion Of Notes Payable Amount StockIssuedForCashAndConversionOfNotesPayableAmount	590000	USD
CY2020Q1	icct	Stock Issued For Services StockIssuedForServices	0	USD
CY2020Q1	icct	Stock Compensation Expense Amount StockCompensationExpenseAmount	95000	USD
CY2020Q1	icct	Stock Issued For Asset Acquisition Of Trinit Note8 Amount StockIssuedForAssetAcquisitionOfTrinitNote8Amount	183000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-780000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	553000	USD
CY2020Q2	icct	Stock Issued For Cash Amount StockIssuedForCashAmount	25000	USD
CY2020Q2	icct	Stock Issued For Conversion Of Note Payable Amount StockIssuedForConversionOfNotePayableAmount	8000	USD
CY2020Q2	icct	Stock Compensation Expense Amount StockCompensationExpenseAmount	225000	USD
CY2020Q2	icct	Stock Issued For Conversion Of Accounts Payable Amount StockIssuedForConversionOfAccountsPayableAmount	250000	USD
CY2020Q2	icct	Stock Issued For Stock Option Exercises Amount StockIssuedForStockOptionExercisesAmount	1000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-857000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	205000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-628940	USD
CY2021Q1	icct	Stock Issued For Cash Amount StockIssuedForCashAmount	1417313	USD
CY2021Q1	icct	Stock Issued For Conversion Of Fees For Services Payable Amount StockIssuedForConversionOfFeesForServicesPayableAmount	481923	USD
CY2021Q1	icct	Stock Compensation Expense Amount StockCompensationExpenseAmount	118796	USD
CY2021Q2	icct	Stock Issued For Asset Acquisition Of Advantech Amount StockIssuedForAssetAcquisitionOfAdvantechAmount	500000	USD
CY2021Q2	icct	Stock Issued For Asset Acquisition Of Bcs Amount StockIssuedForAssetAcquisitionOfBcsAmount	250	USD
	us-gaap	Depreciation Depreciation	5000	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-302057	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	2349546	USD
	us-gaap	Net Income Loss NetIncomeLoss	-1114971	USD
	us-gaap	Net Income Loss NetIncomeLoss	-1637000	USD
	us-gaap	Depreciation Depreciation	1418	USD
	us-gaap	Deferred Sales Inducements Amortization Expense DeferredSalesInducementsAmortizationExpense	469699	USD
	us-gaap	Deferred Sales Inducements Amortization Expense DeferredSalesInducementsAmortizationExpense	443000	USD
	icct	Change In Allowance For Doubtful Accounts ChangeInAllowanceForDoubtfulAccounts	0	USD
	icct	Change In Allowance For Doubtful Accounts ChangeInAllowanceForDoubtfulAccounts	0	USD
	icct	Gain On Cancellation Of Liabilities GainOnCancellationOfLiabilities	-331404	USD
	icct	Gain On Cancellation Of Liabilities GainOnCancellationOfLiabilities	0	USD
	icct	Stock Issued For Services StockIssuedForServices	0	USD
	icct	Stock Issued For Services StockIssuedForServices	0	USD
	us-gaap	Dividends Sharebased Compensation Stock DividendsSharebasedCompensationStock	187741	USD
	us-gaap	Dividends Sharebased Compensation Stock DividendsSharebasedCompensationStock	320000	USD
	icct	Non Cash Interest Expense NonCashInterestExpense	26858	USD
	icct	Non Cash Interest Expense NonCashInterestExpense	12000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-107443	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-73000	USD
	icct	Fixed Assets Increase FixedAssetsIncrease	-4228	USD
	icct	Fixed Assets Increase FixedAssetsIncrease	0	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-111916	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	2000	USD
	icct	Right Of Use Asset Net Of Lease Liability RightOfUseAssetNetOfLeaseLiability	-17448	USD
	icct	Right Of Use Asset Net Of Lease Liability RightOfUseAssetNetOfLeaseLiability	-2000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-11174	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	255000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-23479	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-13000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1036347	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-688000	USD
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	1850022	USD
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	375000	USD
	icct	Additions To Capitalized Software AdditionsToCapitalizedSoftware	-108752	USD
	icct	Additions To Capitalized Software AdditionsToCapitalizedSoftware	-311000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1958774	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-686000	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	1795881	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	416000	USD
	us-gaap	Proceeds From Repayments Of Debt ProceedsFromRepaymentsOfDebt	-875887	USD
	us-gaap	Proceeds From Repayments Of Debt ProceedsFromRepaymentsOfDebt	-71000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2920813	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	595000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1000	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	-7266	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3833541	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	941000	USD
	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	838420	USD
	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	-433000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7619	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	445000	USD
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	846039	USD
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12000	USD
	us-gaap	Interest Paid Net InterestPaidNet	233465	USD
	us-gaap	Interest Paid Net InterestPaidNet	49000	USD
	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	500250	USD
	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	183000	USD
	icct	Stock Issued For Acquisition Of Technology StockIssuedForAcquisitionOfTechnology	0	USD
	icct	Stock Issued For Acquisition Of Technology StockIssuedForAcquisitionOfTechnology	0	USD
	icct	Stock Issued For Conversion Of Convertible Notes Payable StockIssuedForConversionOfConvertibleNotesPayable	0	USD
	icct	Stock Issued For Conversion Of Convertible Notes Payable StockIssuedForConversionOfConvertibleNotesPayable	28000	USD
	icct	Stock Issued For Conversion Of Notes Payable StockIssuedForConversionOfNotesPayable	0	USD
	icct	Stock Issued For Conversion Of Notes Payable StockIssuedForConversionOfNotesPayable	0	USD
	icct	Stock Issued For Conversion Of Accounts Payable StockIssuedForConversionOfAccountsPayable	-7266	USD
	icct	Stock Issued For Conversion Of Accounts Payable StockIssuedForConversionOfAccountsPayable	250000	USD
	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>1. NATURE OF OPERATIONS </strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">iCoreConnect Inc., (the “Company”), a Nevada Corporation, develops and markets secure cloud-based HIPAA compliant software as a service (SaaS) focused on compliance, workflow/productivity, and electronic health records systems. The Company also offers both managed IT (MSP) and managed software as a service (MSaaS) with recurring revenue subscriptions. Our core services technology can be adopted to other vertical markets that require a high degree of secure data communication, such as the legal, financial and education sectors.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Software as a Service (SaaS) Offerings</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company currently markets secure HIPAA compliant cloud-based software as a service (SaaS) offering under the names of iCoreExchange, iCoreCodeGenius, iCoreSecure, iCoreMD, iCoreDental, iCoreMobile, iCoreHuddle, iCoreRx, iCorePDMP, iCoreEPCS, and iCorePay. The Company’s software is sold under annual recurring revenue subscriptions.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>iCoreExchange</strong> – iCoreExchange offers hospitals, physician practices, dental practices, and other healthcare professionals the extensive functionality needed to securely transfer patient health information to anyone, anywhere and at any time. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">iCoreExchange provides a secure, HIPAA compliant email solution using the Direct Protocol that allows doctors to send and receive secure email with attachments to and from other healthcare professionals in the network. iCoreExchange also provides a secure email mechanism to communicate with users outside the exchange e.g., patients and referrals. Users have the ability to build a community, access other communities and increase referrals and collaboration. Users can email standard office documents, JPEG, PDF as well as files with discrete data, Consolidated Clinical Document Architecture (“CCDA”), which can then be imported and accessed on most Electronic Health Record (EHR) and Practice Management systems in a HIPAA compliant manner.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Health Insurance Portability and Accountability Act of 1996 (HIPAA) requires providers and healthcare professionals to transmit encrypted personal health information via electronic means. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>iCoreCodeGenius</strong> – is Coding Software that provides the coding standards for the 10th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD), a medical classification list published by the World Health Organization (WHO). It contains codes for diseases, signs and symptoms, abnormal findings, complaints, social circumstances, and external causes of injury and diseases.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Users can document any medical condition in 60 seconds or less. It includes a full ICD-10 code lookup and guidance, automatic prompting of comorbidities and Hierarchical Condition Category’s (HCC) appropriate reimbursement with a high degree of accuracy, and the ability to reduce or eliminate queries and denials.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>iCoreSecure </strong>–We used our expertise and development capabilities from our HIPAA compliant iCoreExchange and developed iCoreSecure, an encrypted email solution for anyone that needs encrypted email to protect personal and financial data. iCoreSecure solves privacy concerns in the insurance, real estate, financial and many other industry sectors that have a need for secure encrypted email.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>iCoreMD</strong> and <strong>iCoreDental -- </strong>iCoreMD and iCoreDental are complete EHR/Practice Management software platforms created for the medical and dental communities in response to feedback from doctors and dentists telling us they wanted a cloud-based software that was more flexible than the current medical and dental platforms in the marketplace. The software includes patient demographics, scheduling, billing, electronic medical records, electronic claims, e-prescriptions, labs, merchant services, and patient reminders along with a complete suite of standard reporting capabilities and data analytics to help run a medical or dental practice.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our cloud-based software was certified in November 2015 by the Office of the National Coordinator for Health Information Technology (ONC), certificate number 150120r0.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>iCoreMobile -- </strong>iCoreMobile is our third complete EHR software platform, was designed and built specifically for mobile medical and dental care centers. In addition to the features included in iCoreMD and iCoreDental, iCoreMobile also includes workflow optimizations and process enhancements to cater to providers in mobile settings. The software utilizes fully customizable patient intake forms to improve workflow. The software ensures that once a patient’s C-CDA import has been accepted, it is immediately available on all mobile workstations. The enhanced reporting system and metrics provides the main office with extensive data analytics of the mobile unit. The customizable nature of the reporting system allows mobile operators to compare the efficiency of their units.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>iCoreHuddle – </strong>iCoreHuddle is a powerful analytical tool to instantly reveal the revenue potential of each patient. The service connects to most popular practice management and EHR systems to optimize revenue realization. It provides the practice with a dashboard containing various metrics, analytics, and Key Performance Indicators (“KPIs”). iCoreHuddle provides a daily view of patient schedules, including their outstanding balances, uncompleted treatment plans, recall information, procedure information and the amount of remaining insurance benefits. The software also provides one-click access to each patient’s insurance eligibility, including a detailed benefits and deductibles report. This tool aims to increase the workflow efficiency of the dentist’s practice by reducing the number of required lookups and clicks for each patient. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>iCoreRx – </strong>iCoreRx is a HIPAA compliant electronic ePrescription software that integrates with popular practice management and EHR systems. It saves time by selecting exact medications at available doses with built-in support from a drug directory and provides full support for EPCS (electronic prescribed controlled substances). It protects both the patient and provider by viewing the patient’s complete medication history. It also speeds up the process by allowing the doctor to create a “favorites” list for commonly used medication sets. iCorePDMP is an add-on for iCoreRx that seamlessly integrates with state databases to automate prescription drug monitoring. Providers in many states are required to check the patient’s Prescription Drug Monitoring Program (PDMP / PMP) history before prescribing controlled substances. This service provides a one-click real-time access to the state databases without the need to manually enter data and provides access to PDMP data, including a patient’s health history. This tool also generates patient risk scores and an interactive visualization of usage patterns to help the prescriber identify potential risk factors. The prescriber can then use this report to make decisions on objective insight into potential drug misuse or abuse which will ultimately lead to improved patient safety and better patient outcomes.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>IT Managed Services - </strong>The trend in IT Services companies for over a decade has been to model towards “Managed Service Provider (MSP)” and Managed Software as a Services (MSaaS) models with monthly recurring revenue (MRR). </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The MSP approach, by using preventative measures, keeps computers and networks up and running while data is accessible and safeguarded. Installation of critical patches and updates to virus protection are automated. Systems are monitored and backed up in real-time. They are fixed or upgraded before they cause a service disruption. A Unified Threat Management solution is deployed to protect against virus, malware, SPAM, phishing and ransomware attacks. All support is delivered at a predictable monthly cost.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Going forward, by leveraging managed services with our expertise in cloud computing, our customers can easily scale their business without extensive capital investment or disruption in services. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company is competitively positioned to address the growing need for managed services:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our current and future customers need managed IT services, along with cloud computing, storage and HIPAA compliant backup and encryption.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Managed service providers that can support the migration to cloud computing are in high demand.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The decision makers for our current technology and those for managed services are, in many cases, the same person or group of people.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our management team has decades of experience operating successful IT companies.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The MSP revenue model matches our SaaS, MSaaS and MRR models.</p></td></tr></tbody></table>
	icct	Weighted Average Remaining Contractual Term In Years Beginning WeightedAverageRemainingContractualTermInYearsBeginning	P7Y8M12D
	icct	Aggregate Intrinsic Value Beginning AggregateIntrinsicValueBeginning	0	USD
	us-gaap	Derivatives Reporting Of Derivative Activity DerivativesReportingOfDerivativeActivity	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company accounts for derivative instruments in accordance with ASC 815, which requires additional disclosures about the Company’s objectives and strategies for using derivative instruments, how the derivative instruments and related hedged items are accounted for, and how the derivative instruments and related hedging items affect the financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risk. Terms of convertible debt and preferred stock instruments are reviewed to determine whether or not they contain embedded derivative instruments that are required under ASC 815 to be accounted for separately from the host contract and recorded on the balance sheet at fair value. The fair value of derivative liabilities, if any, is required to be revalued at each reporting date, with corresponding changes in fair value recorded in current period operating results.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Freestanding warrants issued by the Company in connection with the issuance or sale of debt and equity instruments are considered to be derivative instruments. Pursuant to ASC 815, an evaluation of specifically identified conditions is made to determine whether the fair value of warrants issued is required to be classified as equity or as a derivative liability.</p>
	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and to the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.</p>
	icct	Going Concerntextblock GoingConcerntextblock	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates continuity of operations, realization of assets, and liquidation of liabilities in the normal course of business.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">For the six-month period ended June 30, 2021, the Company generated an operating loss of $1,164,255. In addition, the Company has an accumulated deficit, total stockholders’ equity and net working capital deficit of $78,995,337, $2,300,261 and $2,106,574, respectively, on June 30, 2021. The Company’s activities were primarily financed through private placements of equity securities. The Company intends to raise additional capital through the issuance of debt and/or equity securities to fund its operations. The Company is reliant on future fundraising to finance operations in the near future. The financing may not be available on terms satisfactory to the Company, if at all. In light of these matters, there is substantial doubt that the Company will be able to continue as a going concern.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Currently, management intends to develop a vastly improved healthcare communications system and intends to develop alliances with strategic partners to generate revenues that will sustain the Company. While management believes in the viability of its strategy to increase revenues and in its ability to raise additional funds, there can be no assurances to that effect. Management’s ability to continue as a going concern is ultimately dependent upon its ability to continually increase the Company’s customer base and realize increased revenues from signed contracts. The financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</p>
	icct	Number Of Options Warrants Outstanding Beginning NumberOfOptionsWarrantsOutstandingBeginning	1405000	shares
	icct	Weighted Average Exercise Price Beginning WeightedAverageExercisePriceBeginning	0.24
	icct	Number Of Options Warrants Outstanding Ending NumberOfOptionsWarrantsOutstandingEnding	1405000	shares
	icct	Weighted Average Exercise Price Ending WeightedAverageExercisePriceEnding	0.24
	icct	Weighted Average Remaining Contractual Term In Years Ending WeightedAverageRemainingContractualTermInYearsEnding	P7Y4M24D
	icct	Aggregate Intrinsic Value Ending AggregateIntrinsicValueEnding	0	USD
	icct	Number Of Options Outstanding Exercisable Ending NumberOfOptionsOutstandingExercisableEnding	1405000	shares
	icct	Weighted Average Exercise Price Exercisable WeightedAverageExercisePriceExercisable	0.24
	icct	Weighted Average Remaining Contractual Term In Years Exercisable Ending WeightedAverageRemainingContractualTermInYearsExercisableEnding	P7Y4M24D
	icct	Weighted Average Grant Date Fair Value Nonvested Beginning WeightedAverageGrantDateFairValueNonvestedBeginning	0
	icct	Weighted Average Remaining Years To Vest Nonvested Begining WeightedAverageRemainingYearsToVestNonvestedBegining	P0Y
	icct	Weighted Average Grant Date Fair Value Nonvested Vested WeightedAverageGrantDateFairValueNonvestedVested	0
	icct	Weighted Average Grant Date Fair Value Nonvested Ending WeightedAverageGrantDateFairValueNonvestedEnding	0
	icct	Weighted Average Remaining Years To Vest Nonvested Ending WeightedAverageRemainingYearsToVestNonvestedEnding	P0Y
	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	9100000	shares
	icct	Summary Of Lease Commitmentstabletextblock SummaryOfLeaseCommitmentstabletextblock	<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td colspan="15" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>iCoreConnect Lease Commitments</strong></p></td></tr><tr style="height:15px"><td colspan="15" style="BORDER-BOTTOM: 1px solid;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>as of 6/30/2021</strong></p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Less than 1 year</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>1-3 years</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>3-5 years</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Total</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>73,980</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="width:20%;vertical-align:bottom;text-align:right;"><strong>57,680</strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="width:20%;vertical-align:bottom;text-align:right;"><strong>0</strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="width:20%;vertical-align:bottom;text-align:right;"><strong>131,660</strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>

Files In Submission

Name	View Source	Status
0001477932-21-005897-index-headers.html	Edgar Link	pending
0001477932-21-005897-index.html	Edgar Link	pending
0001477932-21-005897.txt	Edgar Link	pending
0001477932-21-005897-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
icct-20210630.xsd	Edgar Link	pending
icct-20210630_cal.xml	Edgar Link	unprocessable
icct-20210630_def.xml	Edgar Link	unprocessable
icct-20210630_lab.xml	Edgar Link	unprocessable
icct-20210630_pre.xml	Edgar Link	unprocessable
icct_10q.htm	Edgar Link	pending
icct_10q_htm.xml	Edgar Link	completed
icct_ex25.htm	Edgar Link	pending
icct_ex26.htm	Edgar Link	pending
icct_ex311.htm	Edgar Link	pending
icct_ex312.htm	Edgar Link	pending
icct_ex321.htm	Edgar Link	pending
icct_ex322.htm	Edgar Link	pending
icct_ex55.htm	Edgar Link	pending
icct_ex55img1.jpg	Edgar Link	pending
icct_ex55img10.jpg	Edgar Link	pending
icct_ex55img11.jpg	Edgar Link	pending
icct_ex55img12.jpg	Edgar Link	pending
icct_ex55img2.jpg	Edgar Link	pending
icct_ex55img3.jpg	Edgar Link	pending
icct_ex55img4.jpg	Edgar Link	pending
icct_ex55img5.jpg	Edgar Link	pending
icct_ex55img6.jpg	Edgar Link	pending
icct_ex55img7.jpg	Edgar Link	pending
icct_ex55img8.jpg	Edgar Link	pending
icct_ex55img9.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ICCRW
iCoreConnect Inc. Stock $iccrw

2021 Q3 Form 10-Q Financial Statement

#000147793221005897 Filed on August 23, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ICCRW iCoreConnect Inc. Stock $iccrw

2021 Q3 Form 10-Q Financial Statement

#000147793221005897 Filed on August 23, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ICCRW
iCoreConnect Inc. Stock $iccrw